Jounce Therapeutics Added to NASDAQ Biotechnology Index
Jounce Therapeutics Added to NASDAQ Biotechnology Index Jounce Therapeutics Added to NASDAQ Biotechnology Index CAMBRIDGE, Mass., Dec. 16, 2020 — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotech...
United Kingdom Jounce Therapeutics Inc Exchange Traded Funds Etfs Malin Deon Jounce Therapeutics Inc Gilead Sciences Inc Exchange Commission
Source: globalbankingandfinance.com